News

Home/News

Metrion Biosciences appoints John Montana as Non-Executive Director

2021-02-09T09:05:37+00:00

Metrion Biosciences appoints John Montana as Non-Executive Director Expansion of the Board of Directors will support the company’s further growth as an ion channels focused drug discovery CRO Cambridge, UK, 09 February 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, [...]

Metrion Biosciences appoints John Montana as Non-Executive Director2021-02-09T09:05:37+00:00

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration

2021-02-01T08:45:23+00:00

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration • Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled receptors (GPCRs) • Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise • Joint [...]

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration2021-02-01T08:45:23+00:00

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration

2021-01-18T09:56:07+00:00

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration Ongoing collaboration extended for another 12 months and successfully progresses into late stage hit-to-lead optimisation phase Cambridge and London, UK, 18 January 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent [...]

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration2021-01-18T09:56:07+00:00

Metrion Biosciences Strengthens Global Business Development Team

2020-11-09T20:37:07+00:00

Two appointments in USA and Europe increase representation across key regions Partnership established with On Target Drug Discovery Service and Supply, Ltd. to represent Metrion in Japan Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources [...]

Metrion Biosciences Strengthens Global Business Development Team2020-11-09T20:37:07+00:00

Metrion Biosciences closes funding round

2019-04-01T08:22:36+00:00

Metrion Biosciences Closes Funding Round Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed [...]

Metrion Biosciences closes funding round2019-04-01T08:22:36+00:00

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award

2018-09-10T14:40:22+00:00

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery • Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis • Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors Cambridge, UK, 28 August 2018: Metrion [...]

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award2018-09-10T14:40:22+00:00

Metrion appoints two new Board Directors

2018-08-01T14:30:28+00:00

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Metrion appoints two new Board Directors2018-08-01T14:30:28+00:00

Metrion Biosciences establishes Scientific Advisory Board

2018-11-26T15:28:23+00:00

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences establishes Scientific Advisory Board2018-11-26T15:28:23+00:00

Innovate UK Biomedical Catalyst Feasibility Award

2018-07-18T16:02:11+00:00

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Innovate UK Biomedical Catalyst Feasibility Award2018-07-18T16:02:11+00:00

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.

2018-04-13T13:35:54+00:00

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.2018-04-13T13:35:54+00:00
Go to Top